Angiogenesis: Health and disease

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Bikfalvi, A ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; BEVACIZUMAB; EPHRIN; FIBROBLAST GROWTH FACTOR; NETRIN; NOTCH RECEPTOR; PEGAPTANIB; ROUNDABOUT RECEPTOR; SEMAPHORIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; ARTICLE; CANCER; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIABETIC RETINOPATHY; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; HUMAN; HYPOXIA; ISCHEMIA; LYMPHANGIOGENESIS; NEOVASCULARIZATION (PATHOLOGY); NERVE FIBER GROWTH; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARACRINE SIGNALING; PERICYTE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD VESSELS; HEALTH STATUS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 33749615193     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl239     Document Type: Article

References (56)

1. Rafii S, Lyden D, Benezra R et al. Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-835.
2. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23: 576-582.
3. Alltalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 15: 438(7070).
4. Cao L, Jiao X, Zuzga DS et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 2004; 36: 827-835.
5. Autiero M, De Smet F, Claes F, Carmeliet P. Role of neural guidance signals in blood vessel navigiation. Cardiovasc Res 2005; 65: 629-638.
6. Insight: Angiogenesis. Nature 2005; 438: 889-1050.
7. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005; 218: 1-14.
8. Berra E, Ginouves A, Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep 2006; 7: 41-45.
9. Kalas W, Yu JL, Milsom C et al. Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 2005; 65: 8878-8886.
10. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005; 94: 209-31.
11. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 Suppl 3: 4-10
12. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
13. Suchting S, Bicknell R, Eichmann A. Neuronal clues to vascular guidance. Exp Cell Res 2005 Dec 2; [Epub ahead of print].
14. Lu X, Le Noble F, Yuan L et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature 2004; 432: 179-186.
15. Thurston G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003; 4: 61-68.
16. Hoffmann J, Feng Y, vom Hagen F et al. Endothelial/pericyte interactions. Circ Res 2005; 97: 512-523.
17. Nisato RE, Hosseini G, Sirrenberg C et al. Dissecting the role of matrix metalloproteinases (MMP) and integrin α(v)β3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and α(v)β3 are critical. Cancer Res 2005; 65: 9377-9387.
18. Handsley MM, Edwards DR. Metalloproteinases; and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115: 849-860.
19. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004; 64: 207-238.
20. Tavema D, Crowley D, Connolly M et al. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 2005; 65: 10324-10329.
21. Stupack DG, Cheresh DA. A Bit-role for integrins in apoptosis. Nat Cell Biol 2004; 6: 388-389.
22. Hong YK, Shin JW, Detmar M. Development of the lymphatic vascular system: A mystery unravels. Dev Dyn 2004; 231: 462-473.
23. Oliver G, Alitalo K. The lymphatic vasculature: Recent progress and paradigms. Annu Rev Cell Dev Biol 2005; 21: 457-483.
24. Shin JW, Min M, Larrieu-Lahargue F et al. Prox1 Promotes Lineage-specific expression of Fibroblast Growth Factor (FG)F receptor-3 in lymphatic endothelium: A role for FGF signaling in lymphangiogenesis. Mol Biol Cell 2006; 17: 576-584.
25. Kubo H, Cao R, Brakenhielm E et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induoed lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA 2002; 99: 8868-8873.
26. Chang LK, Garcia-Cardena G, Famebo F et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci USA 2004; 101 11658-11663.
27. Hirakawa S, Kodama S, Kunstfeld R et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201: 1089-1099.
28. Tammela T, Saaristo A, Lohela M et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005; 105: 4642-4648.
29. Bjorndahl M, Cao R, Nissen LJ et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 15593-15598.
30. Cao R, Bjorndahl MA, Gallego MI et al. Hepatocyte growth factor is a novel lymphangiogenic factor with an indirect mechamism of action. Blood 2006 Jan 19; [Epub ahead of print].
31. Petrova TV, Makinen T, Makela TP et al. Free in PMC Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002; 21: 4593-4599.
32. Hirakawa S, Hong YK, Harvey N et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003; 162: 575-686.
33. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
34. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
35. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
36. Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 2005; 54: 53-61.
37. Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer 2003; 3: 411-421.
38. Blouw B, Song H, Tihan T et al. The hypoxic response of tumors is dependent on their microenvronment. Cancer Cell 2003; 4: 133-146.
39. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
40. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 11: 1287-1295.
41. Erber R, Thumher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338-340.
42. Bello L, Carrabba G, Glussani C et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glloma growth in vivo. Cancer Res 2001; 61: 7501-7506.
43. Bussolati B, Deambrosis I, Russo S et al. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17: 1159-1161.
44. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5: 13-17.
45. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
46. Neri D, Bicknell R. Tumour vascular targetirig. Nat Rev Cancer 2005; 5: 436-46.
47. Lin J, Lalani AS, Harding TC et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 2005; 65: 6901-9.
48. Mandriota SJ, Jussila L, Jeltsch M et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-682.
49. Schoppmann SF, Birner P, Stockl J et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161: 947-956.
50. Dadras SS, Paul T, Bertoncini J et al. Tumor lymphangiogenesis: A novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162: 1951-1960.
51. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 1999; 5: 292-297.
52. Fraunfelder FW. Pegaptanib for wet macular degeneration. Drugs Today (Barc) 2005; 41: 703-709.
53. Annex BH, Simons M. Growth factor-induced therapeutic angiogenesis in the heart: Protein therapy. Cardiovasc Res 2005; 65: 649-655.
54. Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690-1699.
55. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005; 17: 293-298.
56. Ranieri G, Ria R, Roccaro AM et al. Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases. Curr Drug Targets Inflamm Allergy 2005; 4: 13-22.